FloBio, founded in 2017 and headquartered in Philadelphia, PA, is dedicated to developing point-of-care diagnostics for assessing bleeding risk through real-time blood analysis. The company's core mission is to provide rapid, precise diagnostic information in emergency, trauma, and critical care settings, where timely and accurate assessment of bleeding and clotting risks can be life-saving. FloBio's innovative technology aims to enhance patient outcomes by enabling swift restoration of hemostasis.
Notable figures associated with FloBio include its founding team and key investors who have supported its growth. The company has achieved significant milestones, such as being a semi-finalist in the 2022 AACC Disruptive Technology Competition and participating in the AACC Annual Scientific Meeting. FloBio's impact lies in its potential to revolutionize emergency medical care by providing critical diagnostic information when every minute counts.
